Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis

Nat Commun. 2022 Oct 4;13(1):5866. doi: 10.1038/s41467-022-33502-7.

Abstract

Uveitis is a severe autoimmune disease, and a common cause of blindness; however, its individual cellular dynamics and pathogenic mechanism remain poorly understood. Herein, by performing single-cell RNA sequencing (scRNA-seq) on experimental autoimmune uveitis (EAU), we identify disease-associated alterations in cell composition and transcriptional regulation as the disease progressed, as well as a disease-related molecule, PIM1. Inhibiting PIM1 reduces the Th17 cell proportion and increases the Treg cell proportion, likely due to regulation of PIM1 to the protein kinase B (AKT)/Forkhead box O1 (FOXO1) pathway. Moreover, inhibiting PIM1 reduces Th17 cell pathogenicity and reduces plasma cell differentiation. Importantly, the upregulation of PIM1 in CD4+ T cells and plasma cells is conserved in a human uveitis, Vogt-Koyanagi-Harada disease (VKH), and inhibition of PIM1 reduces CD4+ T and B cell expansion. Collectively, a dynamic immune cellular atlas during uveitis is developed and implicate that PIM1 may be a potential therapeutic target for VKH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases*
  • Humans
  • Proto-Oncogene Proteins c-akt / metabolism
  • Proto-Oncogene Proteins c-pim-1 / genetics
  • Proto-Oncogene Proteins c-pim-1 / metabolism
  • Th17 Cells
  • Uveitis* / drug therapy
  • Uveitis* / genetics
  • Uveomeningoencephalitic Syndrome* / drug therapy
  • Uveomeningoencephalitic Syndrome* / metabolism

Substances

  • PIM1 protein, human
  • Proto-Oncogene Proteins c-akt
  • Proto-Oncogene Proteins c-pim-1